“We can use our R&D money in better ways,” declared Piaoyang Sun, the CEO and long-reigning chairman of Jiangsu Hengrui Medicine Co. Ltd. and baron of China's domestic drug manufacturing sector.
Speaking at an industry conference, Sun said the time for generics is nearing its end and that companies must now focus on innovation to survive. “The opportunities for generics to...